Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02482324 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by AZTherapies.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT02482324 is a Phase 1 study of Healthy Volunteers that has completed, run by AZTherapies. The registered enrollment target is 26 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02482324, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AZTherapies.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in good general health.

Conditions Studied

Interventions

  • DEVICE Dry Powder Inhaler
  • DRUG ALZT-OP1a
  • DRUG ALZT-OP1b

Study Locations (1)

Florida

  • Panax Clinical Research - Miami Lakes

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2015-06
Est. Completion 2015-07
Phase Phase 1

Sponsor

AZTherapies

4 total trials

What the Registry Record Tells You About NCT02482324

The ClinicalTrials.gov registry entry for NCT02482324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The listed sponsor is AZTherapies, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Dry Powder Inhaler is the first listed.

NCT02482324 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT02482324 about?

NCT02482324 is a clinical study titled "Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers". This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in ...

What is the current status of trial NCT02482324?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-06. Estimated completion is 2015-07.

What conditions does trial NCT02482324 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02482324?

The interventions under investigation include: Dry Powder Inhaler (DEVICE), ALZT-OP1a (DRUG), ALZT-OP1b (DRUG).

Who is sponsoring clinical trial NCT02482324?

This trial is sponsored by AZTherapies, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02482324 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.